Interestingly, SGLT1 and SGLT2 have been associated with the development of diabetes-linked cardiac symptoms and SGLT2 inhibitors have been trialed in recent years as a preventive treatment for HF and other cardiovascular complications [17,18,19,20]. Here, SLC5A2 is linked to diabetes mellitus.